About Hamilton Thorne (CVE:HTL)
Hamilton Thorne Ltd., together with its subsidiary, Hamilton Thorne, Inc., develops, manufactures, and sells precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell, and developmental biology research markets. The company offers clinical lasers, such as LYKOS and ZILOS-tk lasers, as well as clinical laser software and hardware for clinical assisted reproduction; and research lasers, including XYRCOS and XYClone lasers for stem cell research, gene targeting, knock out mouse production, SCNT, ICSI, IVF, and assisted hatching applications, as well as Stiletto lasers for isolation of cells of interest, ablation of unwanted cells, and precision scoring of cell colonies. It also provides clinical sperm analysis (CASA) products comprising IVOS II Clinical and CEROS II Clinical, as well as Human Motility II and Dimensions II Strict Morphology software to clinics, hospitals, and laboratories; animal and research CASA systems, and motility software packages; and various sperm analyzer options. In addition, the company offers sperm analysis accessories, such as Accu-beads+ for use in counting procedures in semen analysis; 2X-CEL disposable semen analysis slides; IDENT Stains for determining sperm motility and concentration; VIADENT stain to determine viable sperm count, concentration, and percentage from a motile sample; and MiniTherm Stage Warmer for CASA and manual sperm motility analysis. Further, it offers IMSI-Strict, an automated software solution for live sperm morphology under high magnification; Oosight imaging system for research purposes; and CIVA, a custom software to capture images/video and annotate. The company sells its products to pharmaceutical and biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Hamilton Thorne Ltd. is based in Beverly, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
SymbolCVE:HTL
CUSIPN/A
Phone+1-978-9212050
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins10.14%
Return on Equity16.18%
Return on Assets7.73%
Miscellaneous
EmployeesN/A
Outstanding Shares107,486,000
Hamilton Thorne (CVE:HTL) Frequently Asked Questions
What is Hamilton Thorne's stock symbol?
Hamilton Thorne trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HTL."
When is Hamilton Thorne's next earnings date?
Who are some of Hamilton Thorne's key competitors?
Some companies that are related to Hamilton Thorne include IRadimed (IRMD), Verona Pharma (VRP), Restoration Robotics (HAIR), Concord Medical Services (CCM), BioXcel Therapeutics (BTAI), Zynerba Pharmaceuticals (ZYNE), MediWound (MDWD), Acer Therapeutics (ACER), Summit Therapeutics (SUMM), Aldeyra Therapeutics (ALDX), Sierra Oncology (SRRA), Bellerophon Therapeutics (BLPH), Pluristem Therapeutics (PSTI), Aeglea Bio Therapeutics (AGLE), Checkpoint Therapeutics (CKPT), BioDelivery Sciences International (BDSI), Organovo (ONVO) and ADOCIA (ADOCY).
Who are Hamilton Thorne's key executives?
Hamilton Thorne's management team includes the folowing people:
- Ms. Meg Spencer, Co-Founder & Chairman
- Mr. David B. Wolf, Chief Exec. Officer, Pres & Director
- Mr. Diarmaid H. Douglas-Hamilton, Co-Founder, CTO, Sr. VP - R&D, Corp. Sec. and Director
- Mr. Michael W. Bruns, CFO & VP - Fin. (Age 61)
- Mr. Keith F. Edwards, Sr. VP & GM
Has Hamilton Thorne been receiving favorable news coverage?
News coverage about HTL stock has been trending somewhat positive on Monday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hamilton Thorne earned a media sentiment score of 0.08 on Accern's scale. They also gave news coverage about the company an impact score of 46.78 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Hamilton Thorne?
Shares of HTL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Hamilton Thorne's stock price today?
One share of HTL stock can currently be purchased for approximately C$0.81.
How big of a company is Hamilton Thorne?
Hamilton Thorne has a market capitalization of C$81.79 million.
How can I contact Hamilton Thorne?
Hamilton Thorne's mailing address is 100 Cummings Ctr Ste 465e, BEVERLY, MA 01915-6143, United States. The company can be reached via phone at +1-978-9212050.
MarketBeat Community Rating for Hamilton Thorne (HTL)
MarketBeat's community ratings are surveys of what our community members think about Hamilton Thorne and other stocks. Vote "Outperform" if you believe HTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hamilton Thorne (CVE:HTL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Hamilton Thorne in the last 12 months. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Hamilton Thorne (CVE:HTL) Consensus Price Target History
Hamilton Thorne (CVE:HTL) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Hamilton Thorne (CVE:HTL) Earnings History and Estimates Chart
Hamilton Thorne (CVE HTL) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/24/2018 | | | | | | | | |
| 11/21/2017 | Q3 2017 | C$0.01 | C$0.01 | C$6.30 million | C$7.59 million | View | N/A |  |
| 4/27/2017 | Q4 2016 | | C$0.01 | C$3.50 million | C$4.83 million | View | N/A | |
| 4/25/2016 | Q4 2015 | | C$0.01 | | C$3.51 million | View | N/A | |
| 4/23/2015 | Q4 2014 | | C$0.01 | | C$3.18 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Hamilton Thorne (CVE:HTL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Hamilton Thorne (CVE HTL) Insider Trading and Institutional Ownership History
Hamilton Thorne (CVE HTL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/29/2018 | Keith Edwards | Insider | Buy | 1,500 | C$0.57 | C$855.00 | | |
| 3/27/2018 | David Wolf | Director | Buy | 10,000 | C$0.57 | C$5,700.00 | | |
| 2/8/2018 | Meg Moray Spencer | Director | Sell | 51,652 | C$0.64 | C$33,057.28 | | |
| 2/6/2018 | Meg Moray Spencer | Director | Sell | 16,500 | C$0.62 | C$10,230.00 | | |
| 1/16/2018 | Keith Edwards | Insider | Buy | 31,250 | C$0.22 | C$6,875.00 | | |
(Data available from 1/1/2013 forward)
Hamilton Thorne (CVE HTL) News Headlines
| Source: |
|
Hamilton Thorne (CVE:HTL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Hamilton Thorne (CVE HTL) Stock Chart for Monday, April, 23, 2018
Loading chart…
